For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of this treatment and Attruby represents a genuine change. These novel therapies preserve the transthyretin protein, halting its destructive build-up and lessening the burden of the disease . Patients are now reporting positive outcomes in